Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) EBITDA (2016 - 2025)

INVO Fertility has reported EBITDA over the past 15 years, most recently at -$1.6 million for Q3 2025.

  • Quarterly EBITDA fell 25.88% to -$1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$18.9 million through Sep 2025, down 210.52% year-over-year, with the annual reading at -$1.8 million for FY2024, 72.96% up from the prior year.
  • EBITDA was -$1.6 million for Q3 2025 at INVO Fertility, up from -$3.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $5.7 million in Q4 2022 and troughed at -$17.1 million in Q1 2025.
  • The 5-year median for EBITDA is -$1.8 million (2024), against an average of -$1.8 million.
  • Year-over-year, EBITDA soared 344.64% in 2021 and then plummeted 1049.64% in 2025.
  • A 5-year view of EBITDA shows it stood at $4.4 million in 2021, then soared by 31.08% to $5.7 million in 2022, then plummeted by 125.98% to -$1.5 million in 2023, then surged by 286.81% to $2.8 million in 2024, then plummeted by 157.73% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IVF's EBITDA are -$1.6 million (Q3 2025), -$3.0 million (Q2 2025), and -$17.1 million (Q1 2025).